Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01335399 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

748

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Dexamethasone
DRUG: Dexamethasone
DRUG: Dexamethasone
BIOLOGICAL: Elotuzumab (BMS-901608; HuLuc63)
BIOLOGICAL: Elotuzumab (BMS-901608; HuLuc63)

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]